NCT05391880View on ClinicalTrials.gov

Study of Orally Administered BEBT-503 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

May 29, 2023

Study Completion Date

July 5, 2023

Conditions
Healthy Subjects
Interventions
DRUG

BEBT-503 20mg

BEBT-503 capsule

DRUG

BEBT-503 40mg

BEBT-503 capsule

DRUG

BEBT-503 80mg

BEBT-503 capsule

DRUG

BEBT-503 120mg

BEBT-503 capsule

DRUG

BEBT-503 180mg

BEBT-503 capsule

DRUG

placebo 20mg

placebo capsule

DRUG

placebo 40mg

placebo capsule

DRUG

placebo 80mg

placebo capsule

DRUG

placebo 120mg

placebo capsule

DRUG

placebo 180mg

placebo capsule

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors

Lead Sponsor

BeBetter Med Inc
All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY